Access to investigational drug for advanced solid tumors

This program provides access to an investigational drug for people who have already been part of the main clinical trial and have no other treatment options. It aims to give continued treatment when regular access is not possible.

This trial offers access to experimental or non-standard cancer treatments for people with advanced solid tumors who have run out of standard options. The goal is to find new ways to treat cancers that are hard to manage.

This trial provides early access to a medication called telisotuzumab adizutecan for people who have run out of other treatment choices. It's for those who cannot join a regular clinical trial but might benefit from this experimental drug.

This Phase 1 trial tests VVD-130037, a new experimental medicine, to see if it is safe and tolerable in people with advanced (metastatic or unresectable) solid cancers. If you have already tried standard treatments and your body can handle study medication, you may be eligible—especially for certain lung, head and neck, or esophageal cancer types with specific genetic changes.

This trial tests a new oral drug (DAT-1604) for people with advanced solid tumors that have stopped responding to other treatments. The goal is to see if it is safe, how the body processes it, and whether it can shrink or slow tumor growth.

This trial tests a new drug, LM-2417, for people with advanced solid tumors that have come back or not responded to treatment. The study will see if LM-2417 is safe and effective, possibly as a new option for those who have run out of standard therapies.